Experience with oxyprothepine in the treatment of manic syndromes.
D000433:1-Propanol / Q000009:adverse effects / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D001714:Bipolar Disorder / Q000188:drug therapy*; D003244:Consciousness Disorders / Q000139:chemically induced; D003693:Delirium / Q000139:chemically induced; D003988:Dibenzothiepins / Q000009:adverse effects / Q000627:therapeutic use*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D013610:Tachycardia / Q000139:chemically induced; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D003988:Dibenzothiepins; D010879:Piperazines; D014149:Tranquilizing Agents; D000433:1-Propanol